NeuroMab™ Anti-PDL1 BBB Shuttle Antibody, Clone NR254P
- Host Species:
- Humanized
- Species Reactivity:
- Human
- Applications:
- In Vitro
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
SPECIFIC INQUIRY
inquiryDescription
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.
Species Reactivity
Clonality
Host Species
Clone Number
Applications
Storage
Research Use Only
Target
Official Name
Alternative Names
Figure 1A shows the effect of oxidation and variable temperature conditions on the exemplary humanized antibody Hu12A11.2b1 and its point mutation at Kabat 99 in CDR-H3.
Figure 1A depicts storage at -80, 5, 25, or 40°C for 30 days or exposure to oxidative conditions (1% hydrogen peroxide, "1% HP"; or 1% tert-butyl hydroperoxide, "1% TBHP" ).
Figure 1B shows the effect of oxidation and variable temperature conditions on the exemplary humanized antibody Hu12A11.2b1 and its point mutation at Kabat 99 in CDR-H3.
Figure 1B depicts the binding of anti-PD-1 antibodies Hu12A11.2b1, Hu12A11.2b2, Hu12A11.2b3 and Hu12A11.2b4
Figure 1C shows the effect of oxidation and variable temperature conditions on the exemplary humanized antibody Hu12A11.2b1 and its Kabat 99 point mutation in CDR-H3.
Figure 1C depicts the binding of Hu12A11.2b4 to PD-1 in Jurkat cells after incubation at -80, 5, 25, or 40°C for 30 days.
Figure 2A shows the biological activity of nivolumab and Hu12A11.2b4 in mixed leukocyte reaction (MLR) and tetanus toxoid antigen recall assays.
Figure 2A shows the increase in IL-2 or interferon-gamma (IFN-gamma) levels following treatment with 10 μg/mL nivolumab, Hu12A11.2b4, or isotype control in mixed leukocyte cultures.
Figure 2B shows the biological activity of nivolumab and Hu12A11.2b4 in mixed leukocyte reaction (MLR) and tetanus toxoid antigen recall assays. Figure 4A shows the increase in IL-2 or interferon-gamma (IFN-gamma) levels following treatment with 10 μg/mL of nivolumab, Hu12A11.2b4, or isotype control in mixed leukocyte cultures. Figure 4B shows the dose-dependent response of nivolumab, Hu12A11.2b4, or isotype control to IFN-γ enhancement in the tetanus toxoid response assay.
Figure 2B shows the dose-dependent response of nivolumab, Hu12A11.2b4, or isotype control to IFN-γ enhancement in the tetanus toxoid response assay.
Publications (0)
